Join
Live feed
·
PRReleasevia Quantisnow
Cartesian Therapeutics Inc. logo
Selecta Biosciences Inc. logo

Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis

ByQuantisnow·Wall Street's wire, on your screen.
RNAC· Cartesian Therapeutics Inc.SELB· Selecta Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RNAC (Cartesian Therapeutics Inc.), SELB (Selecta Biosciences Inc.) and more on Quantisnow.